These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1746 related articles for article (PubMed ID: 31421963)

  • 1. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
    Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
    J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment.
    Granito A; Muratori L; Lalanne C; Quarneti C; Ferri S; Guidi M; Lenzi M; Muratori P
    World J Gastroenterol; 2021 Jun; 27(22):2994-3009. PubMed ID: 34168403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
    Kumar P; Saini S; Prabhakar BS
    Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
    Anderson R; Theron AJ; Rapoport BL
    Front Immunol; 2019; 10():2254. PubMed ID: 31616428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies.
    González-Navajas JM; Fan DD; Yang S; Yang FM; Lozano-Ruiz B; Shen L; Lee J
    Front Immunol; 2021; 12():625783. PubMed ID: 33717139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
    Sasidharan Nair V; Elkord E
    Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treg-mediated acquired resistance to immune checkpoint inhibitors.
    Saleh R; Elkord E
    Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of costimulatory and inhibitory receptors in FoxP3
    Toker A; Ohashi PS
    Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Toxicity of immune checkpoints inhibitors].
    Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
    Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors.
    Grigoriou M; Banos A; Hatzioannou A; Kloetgen A; Kouzis P; Aggouraki D; Zakopoulou R; Bamias G; Kassi E; Mavroudis D; Bamias A; Boumpas DT; Tsirigos A; Gogas H; Alissafi T; Verginis P
    Cancer Immunol Res; 2021 Jul; 9(7):726-734. PubMed ID: 33820810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
    Okiyama N; Tanaka R
    Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
    Kumar P; Bhattacharya P; Prabhakar BS
    J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
    Weinmann SC; Pisetsky DS
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune complications of immunotherapy: pathophysiology and management.
    Chan KK; Bass AR
    BMJ; 2020 Apr; 369():m736. PubMed ID: 32253223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
    Overacre-Delgoffe AE; Vignali DAA
    Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Not Available].
    Senant M; Giusti D; Weiss L; Dragon-Durey MA
    Bull Cancer; 2016 Nov; 103 Suppl 1():S175-S185. PubMed ID: 28057182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular immune responses towards regulatory cells.
    Larsen SK
    Dan Med J; 2016 Jan; 63(1):B5188. PubMed ID: 26726907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
    Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
    Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 88.